Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of subcutaneous ALXN1820 in adults with sickle cell disease
2022-001615-74Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tarperprumig in sickle cell disease (SCD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety and tolerability of ALXN1820 subcutaneous. Started Jan 2023; status: completed.
02
Drugs
tarperprumig
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2022-001615-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001615-74.